Tilburg University

Cognitive rehabilitation in patients with gliomas

Gehring, K.; Sitskoorn, M.M.; Gundy, C.M.; Sikkes, S.A.M.; Klein, M.; Postma, T.J.; van den Bent, M.J.; Beute, G.N.; Enting, R.H.; Kappelle, A.C.; Boogerd, W.; Veninga, T.; Twijnstra, A.; Boerman, D.H.; Taphoorn, M.J.B.; Aaronson, N.K.

Published in:
Journal of Clinical Oncology

Publication date:
2009

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Tilburg University Research Portal](#)

Citation for published version (APA):
Gehring, K., Sitskoorn, M. M., Gundy, C. M., Sikkes, S. A. M., Klein, M., Postma, T. J., van den Bent, M. J., Beute, G. N., Enting, R. H., Kappelle, A. C., Boogerd, W., Veninga, T., Twijnstra, A., Boerman, D. H., Taphoorn, M. J. B., & Aaronson, N. K. (2009). Cognitive rehabilitation in patients with gliomas: A randomized, controlled trial. *Journal of Clinical Oncology*, 27(22), 3712-3722. <http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.20.5765>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial

Karin Gehring, Margriet M. Sitskoorn, Chad M. Gundy, Sietske A.M. Sikkes, Martin Klein, Tjeerd J. Postma, Martin J. van den Bent, Guus N. Beute, Roelien H. Enting, Arnoud C. Kappelle, Willem Boogerd, Theo Veninga, Albert Twijnstra, Dolf H. Boerman, Martin J.B. Taphoorn, and Neil K. Aaronson

From the University Medical Center Utrecht, Rudolf Magnus Institute of Neuroscience, Utrecht; Tilburg University; St Elisabeth Hospital; and Dr Bernard Verbeeten Institute, Tilburg; the Netherlands Cancer Institute; and VU University Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; University Medical Center Groningen, Groningen; Radboud University Nijmegen Medical Center, Nijmegen; University Hospital azM, Maastricht; Rijnstate Hospital Arnhem, Arnhem; and Medical Center Haaglanden, the Hague, the Netherlands.

Submitted October 15, 2008; accepted February 10, 2009; published online ahead of print at www.jco.org on May 26, 2009.

Funded by Grant No. UU2003-2783 from the Dutch Cancer Society; by the Health Insurers Innovation Foundation; and by NeuroCognitief Centrum Nederland (M.M.S.).

Presented in part at the 10th International Psycho-Oncology Society Congress, June 9-13, 2008, Madrid, Spain; the 8th European Association of Neuro-Oncology Congress, September 12-14, 2008, Barcelona, Spain; and the 13th Society for Neuro-Oncology Congress, November 20-23, 2008, Las Vegas, NV.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org

Corresponding author: Neil K. Aaronson, PhD, Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; e-mail: n.aaronson@nki.nl.

© 2009 by American Society of Clinical Oncology

0732-183X/09/2799-1/\$20.00

DOI: 10.1200/JCO.2008.20.5765

ABSTRACT

Purpose

Patients with gliomas often experience cognitive deficits, including problems with attention and memory. This randomized, controlled trial evaluated the effects of a multifaceted cognitive rehabilitation program (CRP) on cognitive functioning and selected quality-of-life domains in patients with gliomas.

Patients and Methods

One hundred forty adult patients with low-grade and anaplastic gliomas, favorable prognostic factors, and both subjective cognitive symptoms and objective cognitive deficits were recruited from 11 hospitals in the Netherlands. Patients were randomly assigned to an intervention group or to a waiting-list control group. The intervention incorporated both computer-based attention retraining and compensatory skills training of attention, memory, and executive functioning. Participants completed a battery of neuropsychological (NP) tests and self-report questionnaires on cognitive functioning, fatigue, mental health–related quality of life, and community integration at baseline, after completion of the CRP, and at 6-month follow-up.

Results

At the immediate post-treatment evaluation, statistically significant intervention effects were observed for measures of subjective cognitive functioning and its perceived burden but not for the objective NP outcomes or for any of the other self-report measures. At the 6-month follow-up, the CRP group performed significantly better than the control group on NP tests of attention and verbal memory and reported less mental fatigue. Group differences in other subjective outcomes were not significant at 6 months.

Conclusion

The CRP has a salutary effect on short-term cognitive complaints and on longer-term cognitive performance and mental fatigue. Additional research is needed to identify which elements of the intervention are most effective.

J Clin Oncol 27. © 2009 by American Society of Clinical Oncology

INTRODUCTION

Gliomas, the most common type of primary brain tumors, and their treatment can cause deficits in various cognitive domains, including attention, memory, and executive functioning.¹⁻³ Although these impairments, in general, are not severe in nature,^{2,4,5} they can have a significant impact on patients' daily lives.⁶ Moreover, subjective cognitive symptoms are among the most common neurologic problems reported by patients with brain tumors.^{7,8}

Pharmacologic interventions have not proven effective yet in the treatment of cognitive deficits in patients with gliomas.⁹ Cognitive rehabilitation interventions represent an alternative treatment approach. Only one small, retrospective study has

investigated cognitive rehabilitation in patients with primary brain tumors.¹⁰ Although the results were positive, they were not based on statistical testing. Cognitive rehabilitation efforts have proven effective in other patient populations, including in those patients with traumatic brain injury,¹¹ stroke,¹¹ and Alzheimer's disease.¹²

This randomized, controlled trial investigated the effectiveness of a multifaceted cognitive rehabilitation program (CRP) on objective and subjective measures of cognitive functioning in patients with gliomas whose diseases were in remission. The primary hypothesis was that patients who underwent the CRP would perform significantly better on objective neuropsychological (NP) tests of attention, memory, and executive functioning and would

report significantly fewer cognitive symptoms than patients in a waiting-list control group. It was also hypothesized that the CRP would have a significant, positive effect on self-reported mental fatigue, mental health-related quality of life (QOL), and community integration.

PATIENTS AND METHODS

Study Sample and Design

Eligible patients were identified via pathology databases or direct referral from 11 Dutch hospitals, including 10 of the 18 Dutch neurosurgical centers. Medical inclusion criteria were as follows: histologically proven or presumed (on the basis of clinical and magnetic resonance imaging features), diffuse, low-grade (ie, WHO grade 2) gliomas (ie, astrocytomas, oligodendrogliomas, or oligoastrocytomas) and age between 18 and 70 years; or anaplastic gliomas, age younger than 50 years, and good performance status (ie, Karnofsky performance score > 70). Patients had to be clinically stable (ie, without any evidence of disease progression) for a minimum of 6 months before study entry, and they could not be receiving antitumor treatment during that period. Exclusion criteria included the following: any additional serious neurologic or psychiatric disorder; inability to undergo the NP assessments (NPAs) or CRP because of premorbid IQ score less than 85; visual, motor, language, or other severe cognitive problems; lack of basic proficiency in Dutch; or participation in a concurrent study with NP testing and/or health-related QOL assessments.

Patients with progressive disease during the course of the study were not automatically excluded from additional participation; this decision was left up to the individual patient.

Medically eligible patients were invited by their physicians to undergo screening for cognitive eligibility (Fig 1). They were screened first via a telephone interview for the presence of subjective cognitive symptoms. Those who reported at least one cognitive symptom from the Medical Outcomes Study (MOS) Cognitive Functioning Scale (CFS)¹³ (Table 1) and who indicated interest in participating in a CRP were referred for objective NP testing. Patients who scored at least one standard deviation less than the mean of a healthy comparison group (N = 294)³⁵ on at least four of 20 objective NP test variables were considered eligible. By employing both subjective and objective cognitive eligibility criteria, it was possible to identify patients who would both be motivated to participate and who would potentially benefit from the CRP.

Patients were assigned to the intervention group or to a waiting-list control group by means of the minimization method,³⁶ which balanced on age, sex, education, tumor grade, hemisphere, radiotherapy, neurosurgery, disease duration, and institution.

To evaluate the effect of the CRP, a battery of NP tests and self-report questionnaires was administered at baseline, directly after cognitive rehabilitation (or an equivalent time point for the control group), and at the 6-month follow-up. Participants were offered the choice of undergoing the NPAs and the CRP sessions in their home or at their hospital. The trial was approved by the institutional review boards of all participating hospitals, and all patients provided written, informed consent.

Fig 1. Flow of participants through the trial (enrollment and attrition). CRP, cognitive rehabilitation program.

Table 1. Objective and Subjective Outcome Measures

Test Name	Subscore or Subtest	Parameter Measured
Objective measures		
Screening tests		
DART (Dutch Adult Reading Test)* ¹⁴		Premorbid intelligence
DMT (Drie-Minuten-Toets) [Three-Minute-Test] ¹⁵		Reading abilities
SCWT (Stroop Color-Word Test)* ^{16,17}	Subtests: Card I, card II, card III, interference	Attention, information processing speed, mental control
LDST (Letter Digit Substitution Test)* ¹⁸	Subtests: Writing, reading, motor	Attention, information processing speed, psychomotor speed
MST (Memory Scanning Test)* ¹⁹	Subscores: Slope, intercept	Speed of memory processes
VVLT (Visual Verbal Learning Test), direct and delayed recall* ²⁰	Subscores: Trial 1, max, delta, total, delayed recall, recognition	Verbal learning and memory
CST (Concept Shifting Test)* ²¹	Subtests: CST-A, CST-B, CST-C, CST-motor	Attention, executive functioning, psychomotor speed
CF (Category Fluency) animals, from the GIT* ²²	Subscore: Number correct	Speed and flexibility of verbal thought process and application of strategies
Neuropsychological tests for the evaluation of intervention effects		
Attention		
SCWT* ^{16,17}	Subtest: Card III (time in seconds)†	Attentional inhibition of a dominant response
DS (Digit Span) from the WAIS-R ²³	Forward (span: 0-8)† Backward (span: 0-7)†	Immediate verbal recall Working memory
LDST* ¹⁸	90 Sec writing (number correct: 0-125)†	Psychomotor speed and speed of information processing
MST* ¹⁹	Slope (time score)† Intercept (time score)†	Time needed for memory scanning Time to complete nonmemory stages
TEA (Test of Everyday Attention) ²⁴	El-Dis (Elevator counting with distraction; number correct: 0-10)†	Auditory selective attention and working memory
Verbal memory		
VVLT, direct and delayed recall* ²⁰	Trial 1 (number correct: 0-15)† Delta (number correct: 0-15)† Delayed recall (number correct: 0-15)†	Immediate verbal span Verbal learning effect Verbal memory after an interval
Executive functions		
CST* ²¹	Subtest: CST-C (time in seconds)†	Alternating attention
LF (Letter Fluency) ²⁵	Score: Number correct (0-∞)†	Speed and flexibility of verbal thought process
CF animals* and professions, from the GIT ²²	Score: Number correct (0-∞)†	Speed and flexibility of verbal thought process and application of strategies
BADS (Behavioural Assessment of the Dysexecutive Syndrome) ^{26,27}	Subtest: Zoo map (profile score: 0-4)†	Planning and priority setting
TEA (Test of Everyday Attention) ²⁴	El-Rev (Elevator counting with reversal; number correct: 0-10)† Tel+Count (Telephone search while counting; decrement in speed due to 2nd task)†	Auditory working memory Divided attention
Subjective measures		
Cognitive symptoms		
CFS (Cognitive Functioning Scale) from the MOS ¹³	Total score (6-36)†	Frequency of cognitive complaints
Burden (study-specific measure)	Total (3-18)† of three questions on the impact of cognitive complaints on daily life, worry about cognitive complaints, being troubled by the cognitive complaints	Burden of CFS complaints
CFQ (Cognitive Failure Questionnaire) ^{28,29}	Total score (0-100)†	Cognitive failures in daily life
SF-36 (Short-Form 36) from the MOS ^{30,31}	Mental component summary score (Mean = 50: SD = 10)†	Mental health-related quality of life
MFI (Multidimensional Fatigue Inventory) ³²	Mental fatigue, reduced activity, reduced motivation (4-20)†	Mental aspects of fatigue
CIQ (Community Integration Questionnaire) ³³	Home integration (0-10), social integration (0-12), productivity (0-7)†	Integration in community
Additional subjective measures		
Motivation	Study-specific measure administered for screening purposes	Motivation to participate in the CRP
Evaluation	Study-specific evaluation form administered after completion of the CRP	Patients' evaluation of the CRP

Screening tests used available normative data (from a sample of 294 individuals comparable to study sample based on age, sex and education).³⁵ Neuropsychological tests were specifically selected for evaluation of possible intervention effects. Subjective measures were self-report questionnaires. Not all screening variables were used as evaluation variables, as some of the screening measures were considered as less relevant for the evaluation of the intervention effect and some other variables did not meet the assumptions for doubly multivariate repeated measures analyses of covariance. Not all tests for evaluation of intervention effects were used as screening measures because of a lack of normative data.

Abbreviations: GIT; Groningen Intelligence Test; WAIS-R, Wechsler Adult Intelligence Scale-Revised; MOS, Medical Outcomes Study; CRP, cognitive rehabilitation program.

*Klein.³⁴

†Higher scores indicate better performance.

‡Higher scores indicate worse performance. Score or scale ranges are in parentheses; ∞ indicates score has no upper limit.

CRP

The CRP consisted of six weekly, individual sessions of 2 hours each. The intervention, carried out by one of seven neuropsychologists, incorporated both cognitive retraining and compensation training (Table 2). For the retraining component, a computer program (C-Car³⁷) was developed, which consisted of a series of hierarchically graded tasks designed to strengthen various aspects of attention on the basis of patient needs. The program focused on attention, because attention deficits are frequently experienced by patients with gliomas,^{38,39} and rehabilitation of attention deficits also may have a salutary effect on other cognitive domains.⁴⁰⁻⁴³ The compensation training component consisted of six psychoeducation sessions that addressed attention, memory, and executive function. These sessions included both didactic and practical elements aimed at helping patients compensate for impaired cognitive functions.

Additional weekly homework assignments consisted of computer-based attention retraining exercises and of logs kept about experiences with applying compensatory strategies in daily life. Approximately 3 months after completion of the CRP, participants had a telephone-based booster session, during which key aspects of the compensation training were re-emphasized.

Control Condition

The waiting-list control group received usual care (ie, regular medical follow-up; no cognitive interventions). Contact with the research staff was at similar intervals as the intervention group, except for the CRP sessions. Control-group patients also received a telephone-based empathy session, during which attention was paid to possible cognitive problems but without explicit advice as to how to deal with them. At completion of the study, participants in the control group were offered the opportunity to undergo the CRP.

Study Measures

Sociodemographic data, including age, sex, and education, were obtained via personal interview. Clinical variables, including tumor characteristics, treatment history, and antiepileptic drug use, were obtained from the medical records.

An extensive battery of NP tests (Table 1) was administered to objectively assess attention, verbal memory, and executive function. Also included were two tests to identify patients with a premorbid IQ less than 85 and/or serious reading problems.

Two self-report questionnaires (Table 1) were used to assess subjective cognitive symptoms and functioning: the MOS CFS,¹³ supplemented by three additional questions on perceived symptom burden (ie, burden) and two questions on motivation to participate in the CRP; and the Cognitive Failure Questionnaire (CFQ), which assessed cognitive problems in daily life.^{28,29} Other self-report measures included the three mental subscales of the Multidimensional Fatigue Inventory (MFI),³² the mental component summary score (MCS) of the Short-Form 36 (SF-36) Health Survey,^{30,31} and the three subscales of the Community Integration Questionnaire (CIQ).³³ After completion of the CRP, patients in the intervention group were queried about their experiences with the program. The NP assessors were blinded to group allocation.

Sample Size Calculations and Statistical Methods

With α set at .05, power at .80, and a minimal Cohen's effect size for between-group differences (d) in the primary outcomes of 0.50, a minimum of 64 patients per group was required.⁴⁴ Independent t tests, χ^2 tests, and Mann-Whitney tests were used to compare group baseline characteristics and to select possible covariates. For the primary statistical analysis, a hierarchical approach

Table 2. Description of the Cognitive Rehabilitation Program

Overall description
Six weekly, individual sessions of approximately 2 hours, plus several hours of homework, provided by a neuropsychologist. Both compensatory strategies (for attention, memory, and executive functioning) and (computer-based attention) retraining
Compensation training
Six integrated psychoeducational lessons addressing attention, memory, and executive function ("planning"), with both didactic and practical/experiential elements. Text chapter was read in advance of the session, the content was discussed in that specific session, and homework was completed afterward and discussed at the start of the next session
Session 1: Cognitive problems; methods of cognitive rehabilitation; compensation: factors influencing cognitive functioning (homework example: keeping a daily log of cognitive problems encountered in daily life)
Session 2: The cognitive functions attention, memory and executive functioning and their interrelationships; compensation techniques: general conditions, strategies and external devices to improve functioning; relaxation exercises (homework examples: finding strategies for cognitive problems noted in daily log; finding personal situations for application of the general conditions, strategies and devices in daily life)
Session 3: Attention and its relevance; strategies for selective, sustained attention, alternating attention, and divided attention; psychological factors of influence (homework example: matching strategies to personal situations, eg, for preventing external distraction)
Session 4: Planning and regulation; designing a plan; strategies for planning an activity; strategies for planning multiple activities (homework examples: application of the 'Seven-Steps-of-Planning-Scheme', planning a busy day)
Session 5: Memory and its functioning; conditions, strategies and external devices (homework example: keeping a log of memory problems and the application of memory strategies to them)
Session 6: Summary of the five former sessions: general overview of the compensation training, re-emphasis of specific conditions, strategies and devices to improve functioning (no homework)
Retraining
For the retraining component, a computer program, 'C-Car' (Concentration Car ¹⁶), was developed by the research team in close collaboration with NeuroCognitief Centrum Nederland
Training of four aspects of attention:
Sustained (prolongation of exercises)
Selective (addition of distraction)
Alternating (alternation between exercises)
Divided (performing multiple tasks simultaneously)
Attractive "game-like" platform (driving an old-timer car and processing information from road signs in changing landscapes)
Exercises in both the visual and the auditory modality; verbal and nonverbal exercises
Tailored to the needs of the individual patient by hierarchical grading of tasks: As soon as the patient has mastered preliminary attentional skills, higher level skills are trained
Real-time feedback to the patient
Automatic registration of a number of outcome variables
Primarily consisting of homework: Exercising ("whenever, wherever") by using a notebook computer

Table 3. Patient Demographics and Disease Characteristics

Characteristic	Intervention Group	Control Group	No. of Patients		P
			Intervention Group	Control Group	
Available for evaluation			70	70	
Age in years*					.303
Mean	42.0	43.8			
Standard deviation	9.4	10.5			
Sex†					.864
Male			41	40	
Female			29	30	
Education†					.898
Low			12	10	
Medium			26	27	
High			32	33	
Disease duration in years‡					.697
Median	5.2	6.1			
Range	38.1	28.3			
Tumor grade†					.820
Low grade (2)			58	59	
Anaplastic (3)			12	11	
Tumor classification†					.953
Astrocytoma			32	35	
Oligodendroglioma			24	21	
Oligoastrocytoma			10	10	
Presumed glioma			4	4	
Hemisphere†					1.000
Left			39	39	
Right			29	29	
Bilateral			2	2	
Surgery†					.931
No			4	4	
Biopsy			21	19	
Resection			45	47	
Cranial irradiation†					1.000
No			27	27	
Yes			43	43	
Chemotherapy†					.785
No			62	63	
Yes			8	7	
Years since last tumor treatment‡					.495
Median	2.6	3.1			
Range	20.6	14.1			
No. of epileptic seizures in the past year‡					.760
Median	2.0	2.0			
Range	2,500	780			
Antiepileptic drug†					.494
No			10	13	
Yes			60	57	
No. of test scores $\geq$ 1 SD below the norm group mean*					.732
Mean	7	7			
SD	13	15			
Progressive disease at NPA2 (N = 135)†					.178
No			59	56	
Yes			7	13	
Progressive disease at NPA3 (N = 127)†§					.007
No			57	44	
Yes			7	19	

The following factors were used for stratification in minimization: patient age, sex, and education; disease duration; tumor grade; hemisphere; surgery; cranial irradiation; and institution (not shown).

Abbreviations: SD, standard deviation; NPA2/3, second/third neuropsychological assessment.

*Independent-samples *t* test.

†Pearson's χ^2 test.

‡Mann-Whitney test.

§Total number of patients in the intervention group with progressive disease at NPA3 = 7 (7 with PD at NPA2 – 2 who subsequently discontinued study participation (see Fig 1) + 2 diagnosed with PD between NPA2 and NPA3). Total number of patients in the control group with progressive disease at NPA3 = 19 (13 with PD at NPA2-3 who subsequently discontinued study participation (Fig 1) + 9 diagnosed with PD between NPA2 and NPA3).

Table 4. Immediate and Longer Term Effects of Cognitive Rehabilitation on Neuropsychological Measures in Patients With Gliomas

Outcome Measure	NPA1 N = 140						NPA2 N = 135				Immediate Effects				NPA3 N = 127				Longer Term Effects			
	Intervention Group			Control Group			Intervention Group		Control Group		<i>P</i>				Intervention Group		Control Group		<i>P</i>			Effect Size <i>d</i>
	Mean	SD	Z ≤ −1	Mean	SD	Z ≤ −1	Mean	SD	Mean	SD	Step 1	Step 2	Step 3	Effect Size <i>d</i>	Mean	SD	Mean	SD	Step 2	Step 3		
Attention																						
Step 1											.028											
Step 2												.463								.004		
SCWT card III	110.94	41.28	44%	119.97	53.92	54%	103.93	37.40	103.29	31.20					103.16	32.61	110.62	27.20		.041	0.23	
DS																						
Forward	5.23	1.08	*	5.14	0.98	*	5.52	1.46	5.52	1.21					5.53	1.19	5.17	0.99		.004	0.43	
Backward	4.49	1.09	*	4.29	0.95	*	4.64	1.36	4.30	1.13					4.74	1.23	4.18	1.02		.001	0.55	
LDST 90 sec																						
writing	43.23	8.74	66%	42.19	9.04	64%	48.49	7.66	47.05	6.39					49.38	8.02	47.12	6.69		.010	0.26	
MST																						
Slope	16.05	10.49	24%	14.67	7.54	24%	13.61	6.73	13.86	5.61					13.82	7.33	15.72	6.12		.095		
Intercept	28.83	8.43	53%	30.67	9.75	54%	27.76	9.25	27.91	7.72					28.09	8.24	28.15	6.87		.692		
TEA EI-Dis	7.32	2.75	*	7.26	2.69	*	8.33	2.39	8.08	1.99					8.32	2.67	7.79	2.23		.078		
Verbal memory																						
Step 1											.015											
Step 2												.323								.009		
VVLT																						
Trial 1	5.77	2.29	13%	5.61	1.66	11%	7.68	2.55	7.46	2.10					8.82	2.78	7.86	2.29		.003	0.48	
Delayed recall	9.17	3.19	27%	8.94	2.95	34%	11.34	3.14	10.87	2.58					12.08	3.32	10.79	2.74		.002	0.43	
Delta	6.20	2.21	34%	5.94	1.70	39%	5.80	2.78	5.38	2.29					4.61	2.62	5.00	2.16		.226		
Executive functions											.218				—							
step 1																						
CST-C	37.13	15.50	34%	39.41	17.30	41%	30.52	17.17	33.22	13.52					35.91	19.83	35.63	16.26		—		
LF	19.41	8.37	*	18.91	8.51	*	21.29	7.29	21.69	5.98					20.59	8.87	20.77	7.27		—		
CF	35.79	7.86	43%	37.31	9.41	33%	37.88	9.48	37.56	7.78					38.61	8.55	36.12	7.01		—		
BADS Zoo map	2.21	1.24	*	2.17	1.30	*	2.46	1.57	2.34	1.29					2.76	1.57	2.46	1.29		—		
TEA EI-Rev	4.64	3.01	*	3.74	2.78	*	5.68	3.10	5.78	2.54					6.34	3.28	5.35	2.70		—		
TEA Tel+Count	1.87	2.76	*	3.79	7.79	*	1.52	3.28	1.40	2.69					1.19	2.49	1.30	2.04		—		

For first neuropsychological assessment (NPA1), raw unadjusted means are shown; for NPA2 and NPA3, means are corrected for covariates. Dashes indicate that models at steps 2 and 3 were not performed because of a statistically nonsignificant result in the prior step.

Abbreviations: Z ≤ -1, percentage of patients out of 70 with score of at least 1 SD below the norm group mean; SD, standard deviation; SCWT, Stroop Color-Word Test; DS, Digit Span; LDST, Letter Digit Substitution Test; MST, Memory Scanning Test; TEA, Test of Everyday Attention; EI-Dis, Elevator Counting with Distraction; VVLT, Visual Verbal Learning Test; CST, Concept Shifting Test; LF, Letter Fluency; CF, Category Fluency; BADS, Behavioural Assessment of the Dysexecutive Syndrome; EI-Rev, Elevator Counting With Reversal; Tel+Count, Telephone Search While Counting.

*No norm group data available.

was used to minimize the possibility of type I errors as a result of multiple testing. First (ie, step 1), six doubly multivariate, repeated-measures analyses of covariance (ANCOVAs)⁴⁵ were conducted on conceptually related objective and subjective measures to investigate group differences over time. The NP tests were clustered into attention, memory, and executive functioning domains (Table 1). The CFS, burden questionnaire, and CFQ were analyzed together, as were the three MFI subscales and the three CIQ subscales. The SF-36 MCS was analyzed separately by using repeated measures ANCOVA.

In step 2, those sets of outcomes that yielded statistically significant between-group differences on the basis of the doubly multivariate, repeated-measures ANCOVAs were submitted to additional statistical testing using multivariate analyses of covariance (MANCOVAs) to determine if observed group differences were present at immediate postintervention and/or at the 6-month follow-up.

In step 3, in those grouped variables for which the simple MANCOVAs yielded significant results at immediate postintervention and/or at 6-month follow-up, a series of ANCOVAs was carried out separately for the individual outcome measures.

In all analyses, relevant baseline values (eg, baseline memory scores when memory test variables were the dependent variables) and possible confounders (eg, disease progression) were included as covariates. The magnitude of statistically significant group differences as analyzed by the ANCOVAs was calculated according to the formula for generalized eta-squared⁴⁶ and was

converted to Cohen's *d* statistic.⁴⁴ According to Cohen's guidelines,⁴⁴ an effect size of 0.20 was considered small, 0.50 was medium, and 0.80 was large.

Additionally, group differences in the proportion of patients that no longer met our criteria for cognitive impairment at both follow-up assessments were analyzed with χ^2 tests. Finally, a subgroup analysis was performed, which excluded patients who experienced disease progression during the course of the study, and a sensitivity analysis was carried out to determine whether the timing of disease progression had an effect on immediate or long-term outcomes.

For all statistical tests, SPSS 15.0.1 (SPSS Inc, Chicago, IL) was used, and *P* less than .05 was considered statistically significant.

RESULTS

Patient Recruitment

Patients were enrolled from November 2004 until December 2006. After various levels of screening (Fig 1), 140 eligible patients were randomly assigned to the intervention group or to the waiting-list control group. During the course of the study, 13 patients (six in the intervention group; seven in the control group) were lost to follow-up, primarily as a result of progressive disease.

Table 5. Immediate and Longer Term Effects of Cognitive Rehabilitation on Subjective Measures in Patients With Gliomas

Outcome Measure	NPA1 (N = 140)		NPA2 (N = 135)		Immediate Effects				NPA3 (N = 127)		Longer Term Effects		
	Intervention Group	Control Group	Intervention Group	Control Group	<i>P</i>				Intervention Group	Control Group	<i>P</i>		
					Step 1	Step 2	Step 3	Effect Size <i>d</i>			Step 2	Step 3	Effect Size <i>d</i>
Cognitive symptoms													
Step 1					.003								
Step 2						.001					.311		
CFS total							.000	0.48					—
Mean	21.01	22.07	25.75	23.34					24.44	23.78			
SD	4.24	4.63	4.50	3.77					6.21	5.20			
Burden total							.009	0.38					—
Mean	9.81	10.76	11.98	10.68					11.96	11.47			
SD	2.85	3.15	3.49	2.93					4.21	3.52			
CFQ total							.014	0.31					—
Mean	47.99	45.99	38.33	43.60					37.58	41.32			
SD	10.31	14.22	12.56	10.52					14.07	11.78			
SF-36 step 1					.165	—							
MCS							—				—		
Mean	42.03*	46.35	46.94	44.21					45.14	43.63			
SD	10.34	9.72	10.68	9.15					12.37	10.60			
MFI													
Step 1					.049								
Step 2						.370					.044		
Mental fatigue												.026	0.41
Mean	15.33*	13.87	11.51	11.44					11.04	11.73			
SD	3.09	4.02	2.42	1.97					2.55	2.08			
Reduced activity												.816	
Mean	12.93*	10.57	12.73	12.18					12.20	12.11			
SD	4.44	4.64	2.25	1.83					2.28	1.86			
Reduced motivation												.063	
Mean	10.94	9.18	11.70	11.88					11.41	12.07			
SD	3.74*	3.67	3.02	2.46					2.65	2.16			
CIQ step 1					0.980	—					—		
Home integration							—					—	
Mean	5.79	5.85	5.97	6.02					5.68	5.75			
SD	2.75	2.77	1.82	1.51					2.05	1.70			
Social integration							—					—	
Mean	8.63	8.63	9.05	8.78					8.65	8.43			
SD	2.42	2.17	2.02	1.68					2.43	2.01			
Productivity							—					—	
Mean	4.03	4.00	4.23	4.21					3.70	3.71			
SD	1.83	1.90	1.25	1.04					1.63	1.35			

For first neuropsychological assessment (NPA1), raw unadjusted means are shown; for NPA2 and NPA3, means are corrected for covariates. Dashes indicate that models at steps 2 and 3 were not performed because of a statistically nonsignificant result in the prior step.

Abbreviations: NPA, neuropsychological assessment; CFS, Cognitive Functioning Scale; SD, standard deviation; CFQ, Cognitive Failure Questionnaire; SF-36, Medical Outcomes Study Short-Form 36; MCS, Mental Component Summary of the Mental Outcomes Study SF-36; MFI, Multidimensional Fatigue Inventory; CIQ, Community Integration Questionnaire.

*Statistically significant group difference at baseline $\alpha = .05$.

Sociodemographic and Clinical Characteristics

No statistically significant differences were observed between groups in sociodemographic or baseline clinical characteristics (Table 3). However, at the third assessment, the incidence of progressive disease was significantly higher in the control group (Table 3). As disease progression at this third assessment was related significantly to two of the outcomes (MFI reduced motivation [$P = .030$] and CIQ total score [$P = .008$], we employed it as a time-varying covariate in all step-1 analyses. For steps 2 and 3, we employed progression at the second NPA (NPA2) as a covariate for

the short-term interval (NPA2 – NPA1) analyses, and progression at the third NPA (NPA3) for the long-term interval (NPA3 – NPA1) analyses.

Baseline NP and Subjective Measures

There were no statistically significant between-group differences in baseline NP test scores (Table 4). However, the intervention group scored significantly worse at baseline on the MFI scales and on the SF-36 MCS (Table 5). As stated in the Patients and Methods section, all baseline scores on the NP tests and subjective measures that were

directly related to the dependent variables were also included as covariates in the analyses.

Overall Effects

Significant group differences over time were observed for objective NP measures of attention ($P = .028$) and verbal memory ($P = .015$; Table 4; Fig 2). Differences in measures of executive functioning were not statistically significant.

For the subjective measures (Table 5; Fig 2), a significant group difference over time was found for the combined analysis of the CFS total score, burden, and CFQ total score ($P = .003$) and for mental aspects of fatigue ($P = .049$). There were no statistically significant group differences over time for the remaining self-report measures.

As these initial analyses had a gatekeeper function, additional statistical testing was carried out only for test scores of attention and

verbal memory (Table 4) and for the self-reported measures of cognitive functioning and mental fatigue (Table 5).

Short-Term NP Outcomes

Immediately post-treatment, there were no statistically significant group differences in attention or verbal memory scores. Both study arms showed similar improvement in most of the attention and memory tests (Fig 2), and the percentage of patients that no longer met criteria for cognitive impairment did not differ between groups (28% v 30% in the intervention and control group, respectively; $P = .801$).

Long-Term NP Outcomes

At the 6-month follow-up, a statistically significant group difference was found for the combined attention tests ($P = .004$). Four of the seven individual attention tests yielded significant

Fig 2. Corrected means and standard errors (bars) of significant objective and subjective intervention effects ($N = 127$). SCWT, Stroop Color-Word Test; DS, Digit Span; LDST, Letter-Digit Substitution Test; VVLT, Visual Verbal Learning Test; CFS, Cognitive Functioning Scale; CFQ, Cognitive Failure Questionnaire; MFI, Multidimensional Fatigue Inventory. (*)Higher scores indicate better performance. (†)Higher scores indicate worse performance.

group differences that favored the CRP group, and effect sizes ranged from 0.23 to 0.55.

Similarly, significant group differences were observed for the combined tests of verbal memory ($P = .009$), and two of the three individual variables yielded significant results that favored the CRP group (effect sizes, 0.48 and 0.43).

The percentage of patients who no longer met criteria for cognitive impairment at the 6-month assessment was 39% in the intervention group versus 21% in the control group ($P = .027$).

Short-Term Subjective Outcomes

Immediately post-treatment, statistically significant differences that favored the intervention group were found in self-reported cognitive functioning (CFS, burden, and CFQ; $P = .001$), and effect sizes ranged from 0.31 to 0.48. There were no significant, short-term group differences in mental fatigue scores.

Long-Term Subjective Outcomes

At the 6-month follow-up, there were no longer statistically significant group differences in self-reported cognitive functioning. The pattern of results (Fig 2) suggests that the CRP group largely maintained its gains in self-reported cognitive functioning, whereas the control group exhibited continued gains over time. Statistically significant group differences that favored the intervention group were observed for the MFI scales ($P = .044$), in particular for mental fatigue (effect size, 0.41).

Subgroup and Sensitivity Analyses

As the number of patients whose disease progressed during the study differed between the groups, a subgroup analysis was performed in which patients with progressive disease ($n = 26$) were excluded. The results indicated significant intervention effects for verbal memory ($P = .048$) and subjective cognitive functioning ($P = .008$). Group differences in attention and mental fatigue were no longer statistically significant. However, it should be noted that these analyses had substantially less statistical power because of the reduced sample size ($n = 101$ v $n = 127$ in the primary analysis).

A sensitivity analysis was performed ($N = 127$), in which it was assumed that progression occurred either at NPA2 or at NPA3. The P values for these (ie, step 2) MANCOVAs per domain were all in the same range (data not shown). This indicated that the timing of disease progression did not affect immediate or long-term outcomes.

Patient Evaluations of CRP

Eighty percent of the patients in the CRP group reported that the content of the program largely/completely addressed their cognitive problems, 87% used the learned compensation strategies regularly/often in daily life, and 79% indicated a decrease in the impact of cognitive problems on daily functioning.

DISCUSSION

In this trial we observed significant improvement in self-reported cognitive functioning at the immediate postintervention assessment, but not at the 6-month follow-up. Conversely, although no significant group differences in NP test scores were observed at the immediate postintervention, clear differences in attention and verbal memory

were found at the 6-month follow-up. The magnitude of the observed effects was moderate. Consistent with these results, the percentage of patients who no longer met criteria for cognitive impairment was similar for both groups at the immediate post-treatment, but the percentage was significantly higher in the CRP group at the 6-month follow-up. Significant intervention effects were also found for long-term mental fatigue scores. The CRP did not have a significant effect on self-reported mental health-related QOL or community integration.

The absence of a significant group effect for the objective NP measures immediately after the intervention may reflect the fact that both study arms exhibited improved objective cognitive performance (ie, attention and memory) in the short term. A practice effect (ie, improved test performance as a result of repeated NP test completion), or regression to the mean, may have initially overwhelmed any intervention effect. At the 6-month assessment, the CRP group exhibited continued improvement in objective cognitive performance, whereas the control group did not. This delayed salutary intervention effect on cognitive performance may indicate that patients require a longer period of time to integrate learned strategies into their daily routine.⁴⁷⁻⁴⁹

The positive effects observed on mental fatigue may reflect a direct effect of the intervention (ie, learned time management strategies) or an indirect effect that results from improved cognitive functioning.

The fact that significant group differences were observed in self-reported cognitive functioning in the short term but not in the long term should be interpreted in light of the pattern of change over time. The CRP group reported a significant improvement in self-reported cognitive functioning early on, and this was largely maintained through to the 6-month follow-up. The control group exhibited a smaller, more gradual improvement in self-reported cognitive functioning over time, which might reflect a combination of regression to the mean,⁵⁰ response shift,⁵¹ and natural recovery (eg,^{52,53}).

The discrepancy observed between objective and subjective cognitive measures is consistent with results of earlier studies among patients with cancer and with other neurologic disorders.^{54,55} In general, self-reported cognitive functioning tends to correlate more highly with self-reported measures of distress and with well-being than with objective NP tests.⁵⁶⁻⁵⁸

Several possible limitations of the study should be noted. First, the study included a relatively large number of outcome measures. This was necessary, given the complex nature of the phenomena under investigation and the current state-of-the-art of NPA. To minimize the possibility of type I errors, we employed a hierarchical approach to the statistical analysis.

Second, the study results can only be generalized to glioma patients who both report having cognitive symptoms and score below a predetermined cutoff on objective NP tests. They may not apply to patients who have significant cognitive impairment on the basis of objective test results, but who do not report cognitive symptoms. Also, the results may apply only to patients with relatively mild deficits, similar to the group studied, who have sufficient cognitive resources and motivation to follow the rehabilitation program. Finally, the study could not tease out the relative effectiveness of cognitive retraining versus the use of compensatory strategies.

In conclusion, this first, randomized, controlled trial of cognitive rehabilitation in patients with gliomas provides initial evidence of a

salutary effect on short-term cognitive complaints and on longer-term cognitive performance and mental fatigue. Future trials are needed to more clearly identify the most effective elements in such a program, to determine how to achieve a sustained, positive effect on cognitive problems in daily life, and to determine the value of such a CRP when used with other patient populations with NP deficits.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

Conception and design: Karin Gehring, Margriet M. Sitskoorn, Martin J.B. Taphoorn, Neil K. Aaronson

Financial support: Margriet M. Sitskoorn

Administrative support: Karin Gehring, Margriet M. Sitskoorn, Sietske A.M. Sikkes, Martin J.B. Taphoorn, Neil K. Aaronson

Provision of study materials or patients: Martin Klein, Tjeerd J. Postma, Martin J. van den Bent, Guus N. Beute, Roelien H. Enting, Arnoud C. Kappelle, Willem Boogerd, Theo Veninga, Albert Twijnstra, Dolf H. Boerman, Martin J.B. Taphoorn

Collection and assembly of data: Karin Gehring, Sietske A.M. Sikkes, Martin Klein

Data analysis and interpretation: Karin Gehring, Margriet M. Sitskoorn, Chad M. Gundy, Martin J.B. Taphoorn, Neil K. Aaronson

Manuscript writing: Karin Gehring, Margriet M. Sitskoorn, Martin J.B. Taphoorn, Neil K. Aaronson

Final approval of manuscript: Karin Gehring, Margriet M. Sitskoorn, Chad M. Gundy, Sietske A.M. Sikkes, Martin Klein, Tjeerd J. Postma, Martin J. van den Bent, Guus N. Beute, Roelien H. Enting, Arnoud C. Kappelle, Willem Boogerd, Theo Veninga, Albert Twijnstra, Dolf H. Boerman, Martin J.B. Taphoorn, Neil K. Aaronson

REFERENCES

- Klein M, Taphoorn MJ, Heimans JJ, et al: Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. *J Clin Oncol* 19:4037-4047, 2001
- Laack NN, Brown PD, Ivnik RJ, et al: Cognitive function after radiotherapy for supratentorial low-grade glioma: A North Central Cancer Treatment Group prospective study. *Int J Radiat Oncol Biol Phys* 63:1175-1183, 2005
- Meyers CA, Brown PD: Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. *J Clin Oncol* 24:1305-1309, 2006
- Anderson SW, Damasio H, Tranel D: Neuropsychological impairments associated with lesions caused by tumor or stroke. *Arch Neurol* 47:397-405, 1990
- Correa DD, Shi W, Thaler HT, et al: Longitudinal cognitive follow-up in low grade gliomas. *J Neurooncol* 86:321-327, 2008
- Meyers CA: Functional outcomes, in Berger MS, Prados M (eds). *Textbook of Neuro-Oncology*. Philadelphia, PA, Elsevier Saunders, 2005, pp 101-104
- Mukand JA, Blackinton DD, Crincoli MG, et al: Incidence of neurologic deficits and rehabilitation of patients with brain tumors. *Am J Phys Med Rehabil* 80:346-350, 2001
- Lidstone V, Butters E, Seed PT, et al: Symptoms and concerns amongst cancer outpatients: Identifying the need for specialist palliative care. *Palliat Med* 17:588-595, 2003
- Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ: Interventions for cognitive deficits in adults with brain tumours. *Lancet Neurol* 7:548-560, 2008
- Sherer M, Meyers CA, Bergloff P: Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. *Cancer* 80:250-257, 1997
- Cicerone KD, Dahlberg C, Malec JF, Langenbahn, et al: Evidence-based cognitive rehabilitation: Updated review of the literature from 1998 through 2002. *Arch Phys Med Rehabil* 86:1681-1692, 2005
- Sitzer DI, Twamley EW, Jeste DV: Cognitive training in Alzheimer's disease: A meta-analysis of the literature. *Acta Psychiatr Scand* 114:75-90, 2006
- Stewart AL, Ware JE, Sherbourne CD, et al: Psychological distress/well-being and cognitive functioning measures, in Stewart AL, Ware JE (eds): *Measuring Functioning and Well-Being: The Medical Outcomes Study Approach*. Durham, NC, Duke University, 1992, pp 102-142
- Schmand BA: The Dutch Adult Reading Test: A Measure of Premorbid Intelligence [in Dutch]. *Tijdschr Gerontol Geriatr* 22:15-19, 1991
- Verhoeven L, Drie-Minuten-Toets (DMT): Handleiding. Arnhem, the Netherlands, Cito, 1995
- Stroop JR: Studies of interference in serial verbal reactions. *J Exp Psychol* 18:643-662, 1935
- Hammes J: The Stroop Color-Word Test: Manual [in Dutch]. Amsterdam, the Netherlands, Harcourt, 1971
- Jolles J, Houx PJ, Van Boxtel MPJ, et al: Maastricht Aging Study: Determinants of Cognitive Aging. Maastricht, the Netherlands, Neuropsych Publishers, 1995
- Brand N, Jolles J: Information processing in depression and anxiety. *Psychol Med* 17:145-153, 1987
- Brand N, Jolles J: Learning and retrieval rate of words presented auditorily and visually. *J Gen Psychol* 112:201-210, 1985
- Vink M, Jolles J: A new version of the trail-making test as an information processing task. *J Clin Neuropsychol* 7:162, 1985
- Luteijn F, Van der Ploeg FAE: Handleiding Groninger intelligentie test (GIT). Lisse, the Netherlands, Swets and Zeitlinger, 1983
- Wechsler D: WAIS-R Manual. New York, NY, Psychological Corp, 1981
- Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I: The Test of Everyday Attention. Bury St Edmunds, United Kingdom, Thames Valley Test Co, 1994
- Lezak MD: Neuropsychological Assessment (ed 3). New York, NY, Oxford University Press, 1995
- Wilson BA, Alderman N, Burgess PW, et al: Behavioural Assessment of the Dysexecutive Syndrome. Bury St Edmunds, United Kingdom, Thames Valley Test Co, 1996
- Krabbendam L, Kalff AC: The Behavioural Assessment of the Dysexecutive Syndrome: Dutch Version. Lisse, the Netherlands, Swets and Zeitlinger, 1998
- Broadbent DE, Cooper PF, FitzGerald P, et al: The Cognitive Failures Questionnaire (CFQ) and its correlates. *Br J Clin Psychol* 21:1-16, 1982
- Ponds RWHM, Rozendaal N, Jolles J: The Cognitive Failure Questionnaire: Factor Structure, Effects of Age, Sex, and Education and the Relation With Cognitive Performance and Psychosocial Variables. Maastricht, the Netherlands, Neuropsych Publishers, 1999
- Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. *Med Care* 30:473-483, 1992
- Aaronson NK, Muller M, Cohen PD, et al: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *J Clin Epidemiol* 51:1055-1068, 1998
- Smets EM, Garssen B, Bonke B, et al: The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. *J Psychosom Res* 39:315-325, 1995
- Waller B, Ottenbacher KJ, Coad ML: The community integration questionnaire: A comparative examination. *Am J Phys Med Rehabil* 73:103-111, 1994
- Klein M, Heimans JJ, Aaronson NK, et al: Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: A comparative study. *Lancet* 360:1361-1368, 2002
- van Boxtel MP, Buntinx F, Houx PJ, et al: The relation between morbidity and cognitive performance in a normal aging population. *J Gerontol A Biol Sci Med Sci* 53:M147-M154, 1998
- Scott NW, McPherson GC, Ramsay CR, et al: The method of minimization for allocation to clinical trials: A review. *Control Clin Trials* 23:662-674, 2002
- Gehring K, Sitskoorn MM: Handleiding C-Car (Manual C-Car). 2004
- Giovagnoli AR, Silvani A, Colombo E, et al: Facets and determinants of quality of life in patients with recurrent high grade glioma. *J Neurol Neurosurg Psychiatry* 76:562-568, 2005
- Kaleita TA, Wellisch DK, Cloughesy TF, et al: Prediction of neurocognitive outcome in adult brain tumor patients. *J Neurooncol* 67:245-253, 2004
- Engelberts NH, Klein M, Ader HJ, et al: The effectiveness of cognitive rehabilitation for attention deficits in focal seizures: A randomized controlled study. *Epilepsia* 43:587-595, 2002
- Strache W: Effectiveness of two modes of training to overcome deficits of concentration. *Int J Rehabil Res* 10:141-145, 1987 (suppl 5)

42. Sohlberg MM, McLaughlin KA, Pavese A, et al: Evaluation of attention process training and brain injury education in persons with acquired brain injury. *J Clin Exp Neuropsychol* 22:656-676, 2000
43. Fasotti L, Kovacs F, Eling PATM, et al: Time pressure management as a compensatory strategy training after closed head injury. *Neuropsychol Rehabil* 10:47-65, 2000
44. Cohen J. *Statistical Power Analysis for the Behavioral Sciences* (ed 2). Hillsdale, NJ, Lawrence Erlbaum Assoc, 1988
45. Tabachnick BG, Fidell LS. *Using Multivariate Statistics* (ed 5). Boston, MA, Pearson/Allyn and Bacon, 2007
46. Olejnik S, Algina J: Generalized eta and omega squared statistics: Measures of effect size for some common research designs. *Psychol Methods* 8:434-447, 2003
47. Gray JM, Robertson I, Pentland B, Anderson S: Microcomputer-based attentional retraining after brain damage: A randomised group controlled trial. *Neuropsychol Rehabil* 2:97-115, 1992
48. Berg JJ, Koning-Haanstra M, Deelman BG: Long-term effects of memory rehabilitation: A controlled study. *Neuropsychol Rehabil* 1:97-111, 1991
49. Wilson BA: Long-term prognosis of patients with severe memory disorders. *Neuropsychol Rehabil* 1:117-134, 1991
50. Bland JM, Altman DG: Regression towards the mean. *BMJ* 308:1499, 1994
51. Sprangers MA, Schwartz CE: Integrating response shift into health-related quality of life research: A theoretical model. *Soc Sci Med* 48:1507-1515, 1999
52. Kolb B: Synaptic plasticity and the organization of behaviour after early and late brain injury. *Can J Exp Psychol* 53:62-76, 1999
53. Lezak MD, Howieson DB, Loring DW, et al. *Neuropsychological Assessment* (ed 4). New York, NY, Oxford University Press, 2004
54. Hermelink K, Untch M, Lux MP, et al: Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. *Cancer* 109:1905-1913, 2007
55. Klein M, Reijneveld JC, Heimans JJ: Subjective ratings vs. objective measurement of cognitive function: In regard to Van Beek et al (*Int J Radiat Oncol Biol Phys* 2007;68:986-991). *Int J Radiat Oncol Biol Phys* 70:961-962, 2008
56. Schagen SB, Boogerd W, Muller MJ, et al: Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. *Acta Oncol* 47:63-70, 2008
57. Castellon SA, Ganz PA, Bower JE, et al: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. *J Clin Exp Neuropsychol* 26:955-969, 2004
58. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. *J Clin Oncol* 20:485-493, 2002

Acknowledgment

We thank the following: Charlotte Bogaerts, Elke Eggens, Ester van der Sluis, Floor Bouwman, Janneke Veefkind, Juriaan Witteman, Lucinda Niezen, Marieke Sikkens, Marylou Apfel, Mathilde Hagen, Sue-Ann Lourens, and Saskia Mulder for carrying out the neuropsychological assessments, cognitive training, and research assistant tasks; Hanneke Zwinkels, Medical Center Haaglanden Den Haag; Lies Braam, VU University Medical Center Amsterdam; Sandra Bossmann, Radboud University Nijmegen Medical Center; Irene Van Heuvel, Erasmus Medical Center Rotterdam; and Irma Koudijs, St Elisabeth Hospital Tilburg, for their help with patient recruitment; Otilia Dalesio and Danny Baars for their expertise in the use of minimization techniques; and Vincent Terlingen, Gijs ten Cate and Arjan Huis in 't Veld for their work on development of the software for the C-Car program. Special thanks to Patrick Maitimo for his supervising role in the programming of C-Car.